Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

NCT ID: NCT05679271

Last Updated: 2025-02-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-22
• Study Completion Date: 2027-12-31

Brief Summary

The goal of this randomized trial to assess the angiographic efficacy of venous stenting in dural arteriovenous fistulae (DAVF) via improvment on Cognard's Classification as compared to no intervention at 6 months Participants belonging to experimental group will be treated using venous stenting. DAVF will be assessed by angiography at 6 months follow-up. Participants belonging to control group will be followed accordingly to standard of care (no treatment). After 6 months, control group patients can be treated by any means accordinlgly to standard of care.

Detailed Description

DAVF are frequently revealed as a cause of invalidating pulsatile tinnitus (PT). Endovascular treatment (EVT) of DAVF using liquid embolic agent (LEA) is currently performed when an hemorrhagic risk of intracranial hemorrhage is identified (high grade DAVF). PT alone may not be a sufficient condition to offer EVT because procedure-related risks may overcome clinical benefits specifically in case of extended shunts requiring complex procedures. Stenting of dural sinus may represent an alternative to LEA-EVT with a simple and low risk procedure. Thus PT could be cured even in case of low grade DAVF without neurologic risk.

Conditions

Pulsatile Tinnitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

venous stenting

Venous stenting associated to antiaggregation protocol:

Venous stenting: venous approach can be performed via femoral, brachial or jugular puncture. Autoexpansible stent should delivered at the level of the fistulous sinus. If distal access catheter is wide enough, stent can be delivered directly through it. After partial deployment of the stent, Labbe vein's flow may be restricted. If necessary, several stents can be used in the same procedure to cover the whole length of fistulous sinus area. After stent deployment, ballon angioplasty is compulsory and must be performed using a ballon of equivalent size to the stent. The procedure ends after stent deployment and angiographic arterial post-op controls.

Antiaggregation protocol: aspirin (160mg for 3 months) + clopidogrel (75mg/d 5 days before stenting and 75mg/d for 1 month after stenting) OR ticagrelor (180mg 2h before stenting and 90mg twice a day for 1 month) in case of clopidogrel platelet resistance.

Group Type: EXPERIMENTAL

Venous stenting

Intervention Type: DEVICE

venous stenting associated to antiaggregation protocol

no treatment

standard care (no treatment)

Group Type: ACTIVE_COMPARATOR

Standard of care

Intervention Type: OTHER

observation: no treatment

Interventions

Venous stenting

venous stenting associated to antiaggregation protocol

Intervention Type: DEVICE

Standard of care

observation: no treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patient presenting invalidating pulsatile tinnitus
• Patient presenting with PT anatomically correlated with a DAVF
• Type I or IIa DAVF on digital subtraction angiography (DSA), according to Cognard's classification.
• DAVF located on sigmoid , lateral or posterior longitudinal sinus.
• Fistula length compatible with use of up to two stents
• Highly effective contraception for women of childbearing potential, maintained during research procedures
• Affiliated or beneficiary of health insurance
• Signed informed consent

Exclusion Criteria

• Patient with DAVF not eligible for endovascular treatment .
• DAVF classification of IIb or more according to Cognard's classification.
• DAVF with severe sinus stenosis or occlusion judged as nor eligible for sinus stenting.
• DAVF showing evidence of recent (inferior to 3 months) thrombophlebitis at the site of fistulous dural sinus.
• Patient with DAVF previously treated with surgery or radiotherapy.
• Patient with multiple DAVF
• Controlateral sinus aplasia or occlusion
• Patient presenting contra-indication to the use of LEA according to the instructions For Use.
• Patient participating in another clinical study evaluating another medical device,
• Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol at 6 months.
• Patient with any known allergy to heparin, acetylsalicylic acid, Coumadin , Warfarin or other antiplatelet medications
• Patient has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
• Patient has had an Intracranial hemorrhage and/or subarachnoid hemorrhage in the past 30 days prior to the study procedure
• Known serious sensitivity to radiographic contrast agents.
• Known sensitivity to nickel, titanium metals, or their alloys
• Known renal failure as defined by a serum creatinine > 2.5 mg/dl (or 220 μmol/l) or glomerular filtration rate (GFR) < 30.
• Patient who has a contraindication to MRI or angiography for whatever reason
• Women who are pregnant, lactating, or who are planning to become pregnant during the anticipated study period
• Patient unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent
• Patient under legal protection

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

French Ministry of Social Affairs and Health

UNKNOWN

Sponsor Role: collaborator

University Hospital, Bordeaux

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU Bordeaux

Bordeaux, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Xavier BARREAU, MD

Role: CONTACT

xavier.barreau@chu-bordeaux.fr

+33 556 79 56 04

Facility Contacts

Xavier Barreau, MD

Role: primary

xavier.barreau@chu-bordeaux.fr

33556795604

Other Identifiers

CHUBX 2022/20

Identifier Type: -

Identifier Source: org_study_id